EXHIBIT 10.3
Portions of this Exhibit have been redacted and are the subject of a
confidential treatment request filed with the Secretary of the Securities and
Exchange Commission.
DISTRIBUTION AGREEMENT AMENDMENT NO. 2
This is the second amendment to the Distribution Agreement ("Distribution
Agreement") made and entered into on January 22, 2002 between:
XXXXXXXX PHARMACEUTICALS LTD., a corporation duly organized and existing under
the laws of England having its place of business at Xxxxxxx Xx, Xxxxxxxxx,
Xxxxxx, Xxxxxx Xxxxxxx XX0 0XX and Xxxxxxxx Pharma Srl, a corporation duly
organized and existing under the laws of Italy having its place of business at
Xxxxx Xxxxxx, 00, 00000 Xxxxxx, Xxxxx. Xxxxxxxx Pharmaceuticals Ltd and
Xxxxxxxx Pharma Srl are hereinafter collectively referred to as "Company"
and
CELL PATHWAYS, INC., a corporation duly organized and existing under the laws
of Delaware having a place of business at 000 Xxxxxxxxxx Xxxxx, Xxxxxxx,
Xxxxxxxxxxxx, 00000 hereinafter referred to as "Distributor."
The Definitions set forth in Article 1 of the Distribution Agreement are used
in and control this Amendment No. 2.
This Amendment No. 2 is effective as of October 15, 2002.
The Company and Distributor agree that as to the order of "at least $2,000,000"
specified in Section 3.1 of the Distribution Agreement, that order shall be
satisfied by amending Distribution Agreement as follows:
Distributor shall pay Company [ ** ] by October 31, 2002;
Company shall deliver to Distributor [ ** ]of Present Product by
December 31, 2002;
Distributor shall pay Company [ ** ] by January 15, 2003;
Company shall deliver to Distributor [ ** ]of Present Product by
March 31, 2003, whereupon Distributor shall pay Company [ ** ]; and
Company shall deliver to Distributor [ ** ]of Present Product by
June 15, 2003, whereupon Distributor shall pay Company [ ** ].
Distributor shall send Company a purchase order substantially in the form
attached on or before October 31, 2002 reflecting the terms above.
The Company and Distributor further agree that Section 9.1 of the Distribution
Agreement shall be amended to allow Distributor to sublicense the GELCLAIR and
XXXXXXXX xxxxx for use on
---------------------------
[**] CONFIDENTIAL TREATMENT REQUESTED; CONFIDENTIAL PORTIONS OMITTED AND FILED
SEPERATELY WITH THE COMMISSION.
Product that are promoted on behalf of Distributor by third parties (e.g., Xxxx
X. Xxxxxx Company under the dental Marketing Agreement between Xxxxxx and
Company dated August 16, 2002 (or amendments thereto)(Cell Pathways' file
C-1639)) in the Territory. Distributor shall oblige any sublicensee to perform
its obligations as to trademark usage in accordance with the provisions of
Article 9 of the Distribution Agreement.
IN WITNESS WHEREOF, the Parties have executed this Amendment No. 2 in
duplicate.
XXXXXXXX PHARMACEUTIALS LTD. CELL PATHWAYS INCORPORATED
Signed by: Xxxxxxx X. Xxxxx Signed by: Xxxxxx X. Xxxxxxxxxx
/s/ /s/
--------------------------- ----------------------------
Position: President & C.E.O. Position: President & C.E.O.
Date: October 15, 2002 Date: October 15, 2002
XXXXXXXX PHARMA SRI
Signed by: Xxxxxxx X. Xxxxx
Position: President
/s/
----------------------
Date: October 15, 2002
3
